Terms: = Prostate cancer AND TP63, EEC3, 8626, ENSG00000073282, p73H, p63, Q9H3D4, TP73L, p51, OFC8, KET, RHS, B p51B , B p51A , SHFM4, LMS, p73L AND Prognosis
17 results:
1. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
2. Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
Ji J; Liu T; Yao Y; Liu W; Ning H; Wang T; Zhang G
Neoplasia; 2024 Jan; 47():100961. PubMed ID: 38142529
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
4. p63-positive prostate carcinoma-A very rare presentation.
Lokesha SB; Chowdary BV; Kini JR
Indian J Pathol Microbiol; 2022; 65(2):448-451. PubMed ID: 35435392
[TBL] [Abstract] [Full Text] [Related]
5. PTEN expression and morphological patterns in prostatic adenocarcinoma.
Spieker AJ; Gordetsky JB; Maris AS; Dehan LM; Denney JE; Arnold Egloff SA; Scarpato K; Barocas DA; Giannico GA
Histopathology; 2021 Dec; 79(6):1061-1071. PubMed ID: 34324714
[TBL] [Abstract] [Full Text] [Related]
6. Possible Usage of p63 in Bioptic Diagnostics.
Galoczová M; Nenutil R; Coates P; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):27-31. PubMed ID: 31023021
[TBL] [Abstract] [Full Text] [Related]
7. New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in prostate Pathology.
Giannico GA; Arnold SA; Gellert LL; Hameed O
Adv Anat Pathol; 2017 Jan; 24(1):35-44. PubMed ID: 27941540
[TBL] [Abstract] [Full Text] [Related]
8. Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Cho MH; Kim SH; Park WS; Joung JY; Seo HK; Chung J; Lee KH
World J Surg Oncol; 2016 Oct; 14(1):270. PubMed ID: 27765044
[TBL] [Abstract] [Full Text] [Related]
9. Epithelioid Angiosarcoma of the Bladder: A Series of 9 Cases.
Matoso A; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1377-82. PubMed ID: 25929352
[TBL] [Abstract] [Full Text] [Related]
10. [Clinicopathologic characteristics of basal cell carcinoma of the prostate: analysis of 5 cases and review of the literature].
Wang Y; Guo P; Liu QS; Xie XC; Gu CY; Jing M; Liu GP
Zhonghua Nan Ke Xue; 2014 Feb; 20(2):160-4. PubMed ID: 24520670
[TBL] [Abstract] [Full Text] [Related]
11. prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics.
Wu A; Kunju LP
Arch Pathol Lab Med; 2013 Sep; 137(9):1179-84. PubMed ID: 23991727
[TBL] [Abstract] [Full Text] [Related]
12. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.
Lotan TL; Gumuskaya B; Rahimi H; Hicks JL; Iwata T; Robinson BD; Epstein JI; De Marzo AM
Mod Pathol; 2013 Apr; 26(4):587-603. PubMed ID: 23222491
[TBL] [Abstract] [Full Text] [Related]
13. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer.
Tucci P; Agostini M; Grespi F; Markert EK; Terrinoni A; Vousden KH; Muller PA; Dötsch V; Kehrloesser S; Sayan BS; Giaccone G; Lowe SW; Takahashi N; Vandenabeele P; Knight RA; Levine AJ; Melino G
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15312-7. PubMed ID: 22949650
[TBL] [Abstract] [Full Text] [Related]
14. Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinoma.
Komura K; Inamoto T; Tsuji M; Ibuki N; Koyama K; Ubai T; Azuma H; Katsuoka Y
Int J Clin Oncol; 2010 Dec; 15(6):594-600. PubMed ID: 20422244
[TBL] [Abstract] [Full Text] [Related]
15. [An update of biomarkers in prostate cancer tissue].
Wang YC; Xia SJ
Zhonghua Nan Ke Xue; 2009 Nov; 15(11):1039-43. PubMed ID: 20218320
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications.
Chivukula M; Domfeh A; Carter G; Tseng G; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):495-9. PubMed ID: 19407654
[TBL] [Abstract] [Full Text] [Related]
17. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody.
Hay RV; Cao B; Skinner RS; Wang LM; Su Y; Resau JH; Knudsen BS; Gustafson MF; Koo HM; Vande Woude GF; Gross MD
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3839S-44S. PubMed ID: 14506181
[TBL] [Abstract] [Full Text] [Related]
